ProCE Banner Events

Share

Vital Questions for Treatment of Bladder Cancer: Expert Insights on Recent and Near-Future Changes

Expert discussions and takeaways for the multidisciplinary management of bladder cancer incorporating the latest clinical advances and guideline updates into the clinic.

In conjunction with the SUO annual meeting.

Evaluation link: education.nccn.org/bladder-symposium 

Who Should Attend

This educational program is intended for urologists, urologic oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals who care for patients with bladder cancer.

Time and location

Wednesday, December 04, 2024

6:45 AM - 8:00 AM Central Time (CT)

In-person

7:00 AM - 8:00 AM Central Time (CT)

Virtual

Sheraton Dallas Hotel
400 Olive Street
Dallas, Texas 75201

Dallas Ballroom D3

Faculty
Fed Ghali, MD

Assistant Professor
Division of Urologic Oncology
Department of Urology
Yale Cancer Center
Yale School of Medicine
New Haven, Connecticut

Tian Zhang, MD, MHS

Associate Professor
Division of Hematology and Oncology
Department of Internal Medicine
Associate Director of Clinical Research
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, Texas

Agenda

Registration & Breakfast: 6:45 am - 7:00 am CT

Symposium: 7:00 am - 8:00 am CT

 

Current Guideline-Recommended Treatments in Nonmetastatic Bladder Cancer

  • Frontline localized therapy options  
  • Therapeutic management of high-risk NMIBC
    • Unresponsive/recurrent NMIBC
    • Rationale for systemic therapy in those nonresponsive to local therapy
    • Vaccines and chemotherapy options
    • Targeted therapies options
  • Investigational studies
  • Comprehensive follow-up strategy
  • Panel discussion

Current Guideline-Recommended Treatments for Advanced Bladder Cancer

  • Guideline recommendation for nonmetastatic muscle-invasive bladder cancer
    • Primary treatment of MIBC
    • Adjuvant treatment of MIBC, following cystectomy (stage II or IIIA)
  • Guideline recommendation for metastatic bladder cancer (stage IV)
    • Primary first-line treatment
    • Sequencing considerations
    • Comprehensive follow-up strategy

Closing Remarks and Question and Answer Session

Location

Venue Name

Sheraton Dallas Hotel

Address

Sheraton Dallas Hotel
400 Olive Street
Dallas, Texas 75201

Room Name

Dallas Ballroom D3

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with bladder cancer. 

Target Audience
This educational program is intended for urologists, urologic oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals who care for patients with bladder cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select therapy for bladder cancer—including non-muscle-invasive, muscle-invasive, locally advanced, and metastatic disease—taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference
  • Plan individualized treatment approaches for patients with nonmetastatic or metastatic bladder cancer that progresses on first-line therapy, based on optimal guideline recommended therapy sequence and assessment of patient and tumor factors that could affect efficacy
  • Monitor patients with bladder cancer on immunotherapy, chemotherapy, or gene therapy for treatment-related adverse events, and employ optimal medical and pharmacologic management strategies
  • Counsel individual patients with non-metastatic or metastatic bladder cancer on the potential for enrollment on ongoing investigational clinical trial based on eligibility, due to failed therapeutic response, unique mechanism of action, or the presence of genetic alterations

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 1.0 contact hour. 

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-24-113-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

For ABIM MOC points, your information will be shared with the ABIM through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to ABIM via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 

Acknowledgement

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by a grant from Pfizer Inc. and Astellas.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.